Signup/Login
If you want to receive notifications of upcoming IPOs, you need to simply sign up or sign in with social networks.
Signup/Login
Can you determine which companies are good and which ones - the trash?
Free Pro-version
IPO Filter
Monitor
IPO today
Twelve Seas Investment Company (TWLVU)
Kensington Capital Acquisition (KCAC.U)
African Gold Acquisition (AGAC.U)
Fusion Acquisition II (FSNB.U)
Mcap Acquisition (MACQU)
Silverbox Engaged Merger I (SBEAU)
Ibere Pharmaceuticals (IBERU)
Freedom Acquisition I (FACT.U)
Arya Sciences Acquisition IV (ARYD)
Warrior Technologies Acquisition Company (WARR.U)
Austerlitz Acquisition Corporation II (ASZ.U)
Austerlitz Acquisition Corporation I (AUS.U)
Leo Holdings III Corp. (LIII.U)
Upcoming IPO
Property Solutions Acquisition II (PSAGU)
Nightdragon Acquisition (NDACU)
Roblox Corporation (RBLX)
Afc Gamma, Inc. (AFCG)
Roth Ch Acquisition III (ROCRU)
Oscar Health, Inc. (OSCR)
Innovage Holding Corp (INNV)
Priced IPO
Score Media And Gaming, Inc. (SCR)
Briacell Therapeutics Corp. (BCTX)
Clip Interactive, LLC (AUDD)
Greenbox Pos (GBOX)
Virpax Pharmaceuticals, Inc. (VRPX)
Urban-gro (UGRO)
Neximmune, Inc. (NEXI)
Longeveron (LGVN)
Talis Biomedical Corporation (TLIS)
Decibel Therapeutics, Inc. (DBTX)
Loandepot, Inc. (LDI)
Bumble, Inc. (BMBL)
Apria, Inc. (APR)
Signify Health, Inc.. (SGFY)
Bioventus Inc. (BVS)
Biophytis SA (BPTS)
Vallon Pharmaceuticals (VLON)
Viant Technology Inc. (DSP)
Global Internet of People (SDH)
Baosheng Media Group Holdings (BAOS)
More companies

Longeveron (LGVN)

Sector - Healthcare

Price chart

-20.6%
Return from IPO

Company News

IPO Profile

About company

They are a clinical stage biotechnology company developing cellular therapies for specific aging-related and life-threatening conditions. Their lead investigational product is the LOMECEL-B™ cell-based therapy product (“Lomecel-B”), which is derived from culture-expanded medicinal signaling cells (MSCs) that are sourced from bone marrow of young healthy adult donors. They believe that by using the same cells that promote tissue repair, organ maintenance, and immune system function, they can develop safe and effective therapies for some of the most difficult disorders associated with the aging process and other medical disorders. They are currently sponsoring Phase 1 and 2 clinical trials in the following indications: Aging Frailty, Alzheimer’s disease, the Metabolic Syndrome, Acute Respiratory Distress Syndrome (ARDS), and hypoplastic left heart syndrome (HLHS). Their mission is to advance Lomecel-B and other cell-based product candidates into pivotal Phase 3 trials, with the goal of achieving regulatory approvals, subsequent commercialization and broad use by the healthcare community.
Industry
Pharmaceuticals
CEO CFO
Geoff Green James Clavijo
Employees Founded
16 2014

Contacts

Address: 1951 NW 7th Avenue, Suite 520 Miami, Florida 33136

Telephone: (305) 909-0840

Web page: http://www.longeveron.com

IPO information

Expected Date 2/12/2021
Status Priced
Exchange NASDAQ
Lockup Period Expiration .Pro
Quiet Period Expiration .Pro
Old Price Range
-
Share prices ($)

Shares & Volumes

Shares Initial (MM) 2.3
Shares Revised (MM) 2.7
Expected offer amount (MM) $30
Realized offer amount(MM) $27

Financial Data (last reporting year)

Market Cap (MM) $187
Revenues (MM) $6.29
Net Income (Loss) (MM) $-2.8

Voting

What do you think will happen with the LGVN share price after the next 3-6 months? 🔥 (+ 10% or more, flat (+ -10%), -10% or less)

Number of votes: img
The lead left underwriter: Kingswood Capital Markets

IPOs led by the firm .Pro
Profitability of conducted IPOs  ?  .Pro
1st day change  ?  .Pro
Change for the first 3 months  ?  .Pro
Underwriters
Kingswood Capital Markets
CO-Managers
Alexander Capital L.P.

Sector: Healthcare

Tweets about $LGVN

Tweets volume:

RT volume:

Timeframe:

Google Trends Stats